In Search of the Optimal Target for Phosphate Control: Episode 1.
作者信息
Wald Ron, Walsh Michael W
机构信息
Division of Nephrology, St. Michael's Hospital, Toronto, Ontario, Canada.
Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
出版信息
J Am Soc Nephrol. 2021 Mar;32(3):526-528. doi: 10.1681/ASN.2021010027. Epub 2021 Feb 5.
Abstract
摘要
相似文献
1
In Search of the Optimal Target for Phosphate Control: Episode 1.探寻磷酸盐控制的最佳靶点：第一集
J Am Soc Nephrol. 2021 Mar;32(3):526-528. doi: 10.1681/ASN.2021010027. Epub 2021 Feb 5.
2
A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.已确立的磷结合剂（钙、司维拉姆和碳酸镧）疗效与安全性的比较综述
Curr Med Res Opin. 2007 Dec;23(12):3167-75. doi: 10.1185/030079907X242719.
3
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.司维拉姆和镧与含钙及铁基结合剂治疗慢性肾脏病患者高磷血症的疗效和安全性：一项系统评价和荟萃分析。
Nephrol Dial Transplant. 2017 Jan 1;32(1):111-125. doi: 10.1093/ndt/gfw312.
4
Hyperphosphatemia and phosphate binders: effectiveness and safety.高磷血症和磷结合剂：有效性和安全性。
Curr Med Res Opin. 2014 Jan;30(1):109-12. doi: 10.1185/03007995.2013.841667. Epub 2013 Oct 9.
5
Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).一项旨在评估新型磷结合剂羟基氧化铁蔗糖在透析患者中的应用，以推进循证医学实践的试验（EPISODE）的原理、设计及特点
Clin Exp Nephrol. 2018 Aug;22(4):967-972. doi: 10.1007/s10157-018-1547-5. Epub 2018 Mar 13.
6
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.在日本高磷血症血液透析患者中，碳酸镧与碳酸钙作为磷结合剂的多中心前瞻性随机双盲对照研究。
Clin Nephrol. 2008 Nov;70(5):404-10. doi: 10.5414/cnp70404.
7
Therapeutic use of the phosphate binder lanthanum carbonate.碳酸镧磷酸盐结合剂的治疗用途。
Expert Opin Drug Metab Toxicol. 2009 Jan;5(1):71-81. doi: 10.1517/17425250802614886.
8
Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.碳酸镧治疗慢性肾脏病（CKD）患者高磷血症的安全性和有效性：一项荟萃分析。
Ren Fail. 2021 Dec;43(1):1378-1393. doi: 10.1080/0886022X.2021.1986068.
9
Optimal use of phosphate binders in chronic kidney disease.慢性肾脏病中磷结合剂的最佳应用。
Expert Opin Pharmacother. 2013 Dec;14(18):2521-32. doi: 10.1517/14656566.2013.852183. Epub 2013 Nov 12.
10
Current and potential treatment options for hyperphosphatemia.高磷血症的当前和潜在治疗选择。
Expert Opin Drug Saf. 2018 Jun;17(6):597-607. doi: 10.1080/14740338.2018.1476487. Epub 2018 May 21.
引用本文的文献
1
Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management.肾衰竭中的高磷血症：病理生理学、挑战及磷管理的关键作用
Nutrients. 2025 May 5;17(9):1587. doi: 10.3390/nu17091587.
2
Tight Phosphate Control in ESKD Patients Is Warranted: Commentary.对终末期肾病患者进行严格的磷酸盐控制是必要的：评论。
Kidney360. 2024 Dec 13;6(6):898-899. doi: 10.34067/KID.0000000661.
3
Unmet needs in clinical trials in CKD: questions we have not answered and answers we have not questioned.慢性肾脏病临床试验中未满足的需求：我们尚未回答的问题以及我们未曾质疑过的答案。
Clin Kidney J. 2022 Oct 15;16(3):437-441. doi: 10.1093/ckj/sfac226. eCollection 2023 Mar.
4
A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care.一项关于年龄对维持性血液透析患者影响的真实世界分析：在常规临床护理中使用蔗糖铁氧体羟化物来管理血清磷。
Int Urol Nephrol. 2023 Feb;55(2):377-387. doi: 10.1007/s11255-022-03327-w. Epub 2022 Aug 11.
Zotero 插件